VBL Therapeutics: Oppenheimer Healthcare Conference (VBL Therapeutics) - Dec 12, 2014 - "VB-201 Exploratory Phase 2 trial in Psoriasis"; "Randomized, double-blind study with 185 patients (US, Germany, Israel)"; "Placebo, 20mg or 80mg of VB-201 for 12 weeks"; "VB-201 found to be safe and well-tolerated"; "Met several secondary endpoints showing statistically significant reduction in disease severity: reduction in PASI, patient global assessment, physician global assessment"; "Clear dose-response, but VB-201 did not reach a plateau"
P2 data • Psoriasis
|